financetom
Business
financetom
/
Business
/
Form 8.3 - American Axle & Manufacturing Holdings Inc
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - American Axle & Manufacturing Holdings Inc
Oct 3, 2025 3:14 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

American Axle & Manufacturing Holdings Inc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

02-10-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

Dowlais Group PLC

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

USD 0.01 common

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

3,263,234

2.74

(2) Cash-settled derivatives:

 

0

0.00

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

0

0.00

3,263,234

2.74

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (USD)

USD 0.01 common

Purchase

200

5.96

USD 0.01 common

Purchase

125

6.00

USD 0.01 common

Purchase

100

6.04

USD 0.01 common

Purchase

130

6.05

USD 0.01 common

Purchase

1010

6.06

USD 0.01 common

Purchase

1

6.06

USD 0.01 common

Purchase

20

6.06

USD 0.01 common

Purchase

1

6.06

USD 0.01 common

Purchase

21

6.06

USD 0.01 common

Purchase

23

6.06

USD 0.01 common

Purchase

2

6.06

USD 0.01 common

Purchase

1

6.06

USD 0.01 common

Purchase

18

6.06

USD 0.01 common

Purchase

1

6.06

USD 0.01 common

Purchase

33

6.06

USD 0.01 common

Purchase

1

6.06

USD 0.01 common

Purchase

32

6.06

USD 0.01 common

Purchase

26

6.07

USD 0.01 common

Purchase

34

6.07

USD 0.01 common

Purchase

27

6.07

USD 0.01 common

Purchase

34

6.07

USD 0.01 common

Purchase

1

6.07

USD 0.01 common

Purchase

1

6.07

USD 0.01 common

Purchase

4

6.07

USD 0.01 common

Purchase

1

6.07

USD 0.01 common

Purchase

3261

6.07

USD 0.01 common

Purchase

21

6.07

USD 0.01 common

Purchase

26

6.07

USD 0.01 common

Purchase

33

6.07

USD 0.01 common

Purchase

13

6.07

USD 0.01 common

Purchase

28

6.07

USD 0.01 common

Purchase

49

6.07

USD 0.01 common

Purchase

4

6.07

USD 0.01 common

Purchase

21

6.07

USD 0.01 common

Purchase

21

6.07

USD 0.01 common

Purchase

12

6.07

USD 0.01 common

Purchase

10

6.07

USD 0.01 common

Purchase

24

6.07

USD 0.01 common

Purchase

22

6.07

USD 0.01 common

Purchase

101

6.08

USD 0.01 common

Purchase

10

6.08

USD 0.01 common

Purchase

29

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

23

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

42

6.08

USD 0.01 common

Purchase

28

6.08

USD 0.01 common

Purchase

36

6.08

USD 0.01 common

Purchase

16221

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

1

6.08

USD 0.01 common

Purchase

23

6.08

USD 0.01 common

Purchase

26

6.08

USD 0.01 common

Purchase

3

6.08

USD 0.01 common

Purchase

196

6.08

USD 0.01 common

Purchase

27

6.08

USD 0.01 common

Purchase

8

6.08

USD 0.01 common

Purchase

174

6.08

USD 0.01 common

Purchase

30

6.08

USD 0.01 common

Purchase

29

6.08

USD 0.01 common

Purchase

160

6.08

USD 0.01 common

Purchase

200

6.08

USD 0.01 common

Purchase

26

6.09

USD 0.01 common

Purchase

26

6.09

USD 0.01 common

Purchase

1

6.09

USD 0.01 common

Purchase

12

6.09

USD 0.01 common

Purchase

1057

6.09

USD 0.01 common

Purchase

200

6.09

USD 0.01 common

Purchase

365

6.10

USD 0.01 common

Purchase

100

6.11

USD 0.01 common

Purchase

12

6.11

USD 0.01 common

Purchase

4

6.11

USD 0.01 common

Purchase

7

6.11

USD 0.01 common

Purchase

16

6.11

USD 0.01 common

Purchase

22

6.11

USD 0.01 common

Purchase

100

6.12

USD 0.01 common

Purchase

11

6.12

USD 0.01 common

Purchase

100

6.12

USD 0.01 common

Purchase

120

6.13

USD 0.01 common

Purchase

5

6.15

USD 0.01 common

Purchase

11

6.16

USD 0.01 common

Purchase

205

6.17

USD 0.01 common

Purchase

175

6.18

USD 0.01 common

Purchase

210

6.19

USD 0.01 common

Sale

100

5.96

USD 0.01 common

Sale

300

6.04

USD 0.01 common

Sale

600

6.05

USD 0.01 common

Sale

671

6.06

USD 0.01 common

Sale

34

6.07

USD 0.01 common

Sale

3914

6.07

USD 0.01 common

Sale

14

6.08

USD 0.01 common

Sale

10182

6.08

USD 0.01 common

Sale

4459

6.09

USD 0.01 common

Sale

1200

6.10

USD 0.01 common

Sale

823

6.11

USD 0.01 common

Sale

536

6.12

USD 0.01 common

Sale

79

6.13

USD 0.01 common

Sale

81

6.15

USD 0.01 common

Sale

607

6.16

USD 0.01 common

Sale

992

6.17

USD 0.01 common

Sale

303

6.18

USD 0.01 common

Sale

37

6.19

USD 0.01 common

Sale

66

6.19

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

USD 0.01 common

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

3,263,234

2.74

(2) Cash-settled derivatives:

 

0

0.00

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

0

0.00

3,263,234

2.74

0

Class of relevant security:

 

USD 0.01 common

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

3,263,234

2.74

(2) Cash-settled derivatives:

 

0

0.00

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

0

0.00

3,263,234

2.74

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: US DoJ's Antitrust Division Does Not Plan to Fast Track Approval for Paramount Skydance, Warner Bros. Discovery Merger
Market Chatter: US DoJ's Antitrust Division Does Not Plan to Fast Track Approval for Paramount Skydance, Warner Bros. Discovery Merger
Mar 19, 2026
05:25 AM EDT, 03/19/2026 (MT Newswires) -- The US Department of Justice's antitrust division does not plan to fast track the approval for Paramount Skydance's ( PSKY ) planned acquisition of Warner Bros. Discovery ( WBD ) due to political issues, Reuters reported Wednesday, citing the acting head of the antitrust division, Omeed Assefi. Assefi made the remarks during an...
Form 8.3
Form 8.3
Mar 19, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed,...
Evotec Receives $10 Million Milestone Payment From Bristol-Myers Squibb
Evotec Receives $10 Million Milestone Payment From Bristol-Myers Squibb
Mar 19, 2026
04:47 AM EDT, 03/19/2026 (MT Newswires) -- Evotec (EVO) said Thursday it will receive a $10 million milestone payment from partner Bristol-Myers Squibb ( BMY ) following the initiation of an early-stage clinical trial for a kidney cancer treatment. The initial phase study is evaluating a jointly developed protein degradation candidate for the treatment of advanced clear cell renal cell...
From chemical producers to sento baths, Japan feels the heat from Middle East supply crisis
From chemical producers to sento baths, Japan feels the heat from Middle East supply crisis
Mar 19, 2026
* Japan gets around 90% of its oil from the Middle East * Opened taps for a record oil stockpile release on Monday * Petrochemicals, steel, refineries and even sento baths are hit By Katya Golubkova and Mariko Katsumura TOKYO, March 19 (Reuters) - Japanese companies, from steel producers to chemical firms and even sento baths, are feeling the heat...
Copyright 2023-2026 - www.financetom.com All Rights Reserved